Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Treatment with 5-Azacytidine in High Risk MDS, CMML and AML: A Single Center Analysis with Regard to Days in Hospital and Days in Outpatient Clinic

Corinna Strupp, Annika Kasprzak, Andrea Kündgen, Fabian Czerwensky, Sascha Dietrich, Ulrich Germing

Blood (2024) 144 (Supplement 1): 7636.

https://doi.org/10.1182/blood-2024-205650

Published: 2024

Journal Articles

Rapid, Reliable, and Comprehensive Identification of MDS-Defining Cytogenetic Changes By a FISH-Panel Containing Six Probes in a Real-World Population of Patients with Suspected AML

Katayoon Shirneshan, Hannes Treiber, Katharina Rittscher, Ulrich Germing, Barbara Hildebrandt, Corinna Strupp, Julie Schanz, Ute Windolph, Christina Ganster, Detlef Haase

Blood (2024) 144 (Supplement 1): 4308.

https://doi.org/10.1182/blood-2024-194186

Published: 2024

Journal Articles

Comparison of Cytomorphology and Histopathology in Myelodysplastic Syndromes (MDS)

Kathrin Nachtkamp, Corinna Strupp, Rosa Faoro, Norbert Gattermann, Ulrich Germing, Stephan E Baldus

Blood (2022) 140 (Supplement 1): 12345–12346.

https://doi.org/10.1182/blood-2022-166172

Published: 2022

Journal Articles

Increased Bone Marrow Iron at Diagnosis Is Associated with Inferior Prognosis in Patients with Myelodysplastic Syndromes

Annika Kasprzak, Sandra Becker, Martina Rudelius, Corinna Strupp, Kathrin Nachtkamp, Judith Strapatsas, Barbara Hildebrandt, Norbert Gattermann, Ulrich Germing

Blood (2021) 138 (Supplement 1): 3700.

https://doi.org/10.1182/blood-2021-152402

Published: 2021

Journal Articles

Molecular Profile and Cytomorphological Manifestation of Isolated Y Loss in Myelodysplastic Syndromes

Blood (2018) 132 (Supplement 1): 4358.

https://doi.org/10.1182/blood-2018-99-114216

Published: 2018

Journal Articles

Additional Prognostic Impact of the Percentage of Erythroid Cells in the Bone Marrow of MDS Patients

Judith Neukirchen, MD, Heinz Tuechler, Matteo Giovanni Della Porta, MD, Pierre Fenaux, MD PhD, Ulrich Germing, MD, Agnès Guerci, Kathrin Nachtkamp, MD, Marianna Rossi, MD, Rosa Sapena, Wolfgang R. Sperr, MD, Corinna Strupp, MD, Aspasia Stamatoullas, MD, Peter Valent, MD, John M. Bennett, MD

Blood (2017) 130 (Supplement 1): 4259.

https://doi.org/10.1182/blood.V130.Suppl_1.4259.4259

Published: 2017

Journal Articles

RBC-Transfusion Dependency Improves the Prognostic Value of the Revised-IPSS in MDS Patients: Analysis of South Australian and Dusseldorf MDS Registries

Deepak Singhal, MD FRCPA, Corinna Strupp, Rakchha Chhetri, MBBS, Monika M Kutyna, MSc, L Amilia Wee, B.Sc(Hons), Shriram V. Nath, FRCPA, DM, MD, Nicholas Wickham, FRCPA, FRACP, FRCPath, Chi-hung Hui, MBBS, MRCP, FRCPath, FRACP, FRCPA, James X Gray, MD PhD, David M. Ross, MBBS, PhD FRACP, FRCPA, Ian D Lewis, MBBS, PhD FRACP, FRCPA, Peter G Bardy, MBBS, FRACP, FRCPA, John Reynolds, PhD, Luen Bik To, MBBS, PhD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Ulrich Germing

Blood (2016) 128 (22): 1998.

https://doi.org/10.1182/blood.V128.22.1998.1998

Published: 2016

Journal Articles

Survey of Treatment of 1021 Patients with Myelodysplastic Syndromes in a Tertiary Referal Center 2007-2013

Jennifer Schemenau, Kathrin Nachtkamp, MD, Blanca Xicoy, MD PhD, Andrea Kuendgen, MD, Corinna Strupp, MD, Thomas Schroeder, MD, Esther Schuler, Guido Kobbe, MD, Norbert Gattermann, MD, Rainer Haas, MD, Ulrich Germing

Blood (2014) 124 (21): 4647.

https://doi.org/10.1182/blood.V124.21.4647.4647

Published: 2014

Journal Articles

In MDS Del(5q), Factors Other Than Age and Sex Distribution Contribute to the Prognostic Advantage, Which Diminishes over Time

Michael Lauseker, PhD, Jennifer Schemenau, Corinna Strupp, MD, Andrea Kuendgen, MD, Norbert Gattermann, MD, Joerg Hasford, MD, Ulrich Germing, MD

Blood (2014) 124 (21): 3271.

https://doi.org/10.1182/blood.V124.21.3271.3271

Published: 2014

Journal Articles

Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value

Alexander E. Smith, Azim M. Mohamedali, Austin Kulasekararaj, ZiYi Lim, Joop Gäken, Nicholas C. Lea, Bartlomiej Przychodzen, Syed A. Mian, Erick E. Nasser, Claire Shooter, Nigel B. Westwood, Corinna Strupp, Norbert Gattermann, Jaroslaw P. Maciejewski, Ulrich Germing, Ghulam J. Mufti

Blood (2010) 116 (19): 3923–3932.

https://doi.org/10.1182/blood-2010-03-274704

Published: 2010

Includes: Supplemental data

Journal Articles

Matched-Pair Analysis of 186 MDS Patients Receiving Iron Chelation Therapy or Transfusion Therapy Only.

Frank Fox, Andrea Kündgen, Kathrin Nachtkamp, Corinna Strupp, Rainer Haas, Ulrich Germing, Norbert Gattermann, MD, PhD

Blood (2009) 114 (22): 1747.

https://doi.org/10.1182/blood.V114.22.1747.1747

Published: 2009

Journal Articles

Deep Sequencing the Tet2 Gene in 360 Patients with Myeloid Neoplasms Provides a Comprehensive and Quantitative Mutation Map and Reveals Low Level Mutant Clones.

Alexander E Smith, Azim M Mohamedali, PhD, Syed a Mian, Technician, Nicholas C Lea, BSc, PhD, Nigel Westwood, PhD, CSci, FIBMS, Austin G Kulasekararaj, Joop Gaken, PhD, Corinna Strupp, Norbert Gattermann, MD, PhD, Ulrich Germing, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath

Blood (2009) 114 (22): 733.

https://doi.org/10.1182/blood.V114.22.733.733

Published: 2009

Journal Articles

Varying Importance of Prognostic Factors in Subgroups of Myelodysplastic Syndromes Defined by Blast Count, Cytogenetic Risk Group, or WHO Classification.

Andrea Kuendgen, Corinna Strupp, Kathrin Nachtkamp, Barbara Hildebrandt, Rainer Haas, Norbert Gattermann, Ulrich Germing

Blood (2009) 114 (22): 2776.

https://doi.org/10.1182/blood.V114.22.2776.2776

Published: 2009

Journal Articles

Clinical Outcome of 40 Patients with Higher-Risk Myelodysplastic Syndromes (MDS) after Treatment with Hypomethylating Agents: a Matched-Pairs Analysis

Kathrin Nachtkamp, Corinna Strupp, Andrea Kuendgen, Norbert Gattermann, Rainer Haas, Ulrich Germing

Blood (2008) 112 (11): 2687.

https://doi.org/10.1182/blood.V112.11.2687.2687

Published: 2008

Journal Articles

Characteristics of Disease Progression in 3213 Patients with Myelodysplastic Syndrome

Fabian Zohren, Corinna Strupp, Andrea Kuendgen, Aristoteles Giagounidis, Barbara Hildebrandt, Ulrich Suter, Norbert Gattermann, MD, Rainer Haas, Ulrich Germing

Blood (2008) 112 (11): 2689.

https://doi.org/10.1182/blood.V112.11.2689.2689

Published: 2008

Journal Articles

A WHO Classification-Based Prognostic Scoring System (WPSS) for Predicting Survival in Myelodysplastic Syndromes.

Luca Malcovati, MD, Ulrich Germing, MD, Andrea Kuendgen, MD, Matteo G. Della Porta, MD, Rosangela Invernizzi, MD, Aristoteles Giagounidis, MD, Barbara Hildebrandt, PhD, Paolo Bernasconi, MD, Sabine Knipp, MD, Mario Lazzarino, MD, Corinna Strupp, MD, Mario Cazzola, MD

Blood (2005) 106 (11): 788.

https://doi.org/10.1182/blood.V106.11.788.788

Published: 2005

Journal Articles

Phase 2 Trial of the Histone Deacetylase Inhibitor Valproic Acid as a Monotherapy or in Combination with All-Trans Retinoic Acid in 24 Patients with Acute Myeloid Leukemia.

Andrea Kuendgen, MD, Corinna Strupp, MD, Barbara Hildebrandt, PhD, Sabine Knipp, MD, Baerbel Junge, Rainer Haas, MD, Ulrich Germing, MD, Norbert Gattermann, MD

Blood (2004) 104 (11): 1808.

https://doi.org/10.1182/blood.V104.11.1808.1808

Published: 2004

Journal Articles

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all- trans retinoic acid

Andrea Kuendgen, Corinna Strupp, Manuel Aivado, Alf Bernhardt, Barbara Hildebrandt, Rainer Haas, Ulrich Germing, Norbert Gattermann

Blood (2004) 104 (5): 1266–1269.

https://doi.org/10.1182/blood-2003-12-4333

Published: 2004

Journal Articles

New prognostic parameters for chronic myelomonocytic leukemia?

Ulrich Germing, Corinna Strupp, Manuel Aivado, Norbert Gattermann

Blood (2002) 100 (2): 731–733.

https://doi.org/10.1182/blood-2002-01-0330

Published: 2002

NARROW

Treatment with 5-Azacytidine in High Risk MDS, CMML and AML: A Single Center Analysis with Regard to Days in Hospital and Days in Outpatient Clinic

Rapid, Reliable, and Comprehensive Identification of MDS-Defining Cytogenetic Changes By a FISH-Panel Containing Six Probes in a Real-World Population of Patients with Suspected AML

Comparison of Cytomorphology and Histopathology in Myelodysplastic Syndromes (MDS)

Increased Bone Marrow Iron at Diagnosis Is Associated with Inferior Prognosis in Patients with Myelodysplastic Syndromes

Molecular Profile and Cytomorphological Manifestation of Isolated Y Loss in Myelodysplastic Syndromes

Additional Prognostic Impact of the Percentage of Erythroid Cells in the Bone Marrow of MDS Patients

RBC-Transfusion Dependency Improves the Prognostic Value of the Revised-IPSS in MDS Patients: Analysis of South Australian and Dusseldorf MDS Registries

Survey of Treatment of 1021 Patients with Myelodysplastic Syndromes in a Tertiary Referal Center 2007-2013

In MDS Del(5q), Factors Other Than Age and Sex Distribution Contribute to the Prognostic Advantage, Which Diminishes over Time

Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value

Matched-Pair Analysis of 186 MDS Patients Receiving Iron Chelation Therapy or Transfusion Therapy Only.

Deep Sequencing the Tet2 Gene in 360 Patients with Myeloid Neoplasms Provides a Comprehensive and Quantitative Mutation Map and Reveals Low Level Mutant Clones.

Varying Importance of Prognostic Factors in Subgroups of Myelodysplastic Syndromes Defined by Blast Count, Cytogenetic Risk Group, or WHO Classification.

Clinical Outcome of 40 Patients with Higher-Risk Myelodysplastic Syndromes (MDS) after Treatment with Hypomethylating Agents: a Matched-Pairs Analysis

Characteristics of Disease Progression in 3213 Patients with Myelodysplastic Syndrome

A WHO Classification-Based Prognostic Scoring System (WPSS) for Predicting Survival in Myelodysplastic Syndromes.

Phase 2 Trial of the Histone Deacetylase Inhibitor Valproic Acid as a Monotherapy or in Combination with All-Trans Retinoic Acid in 24 Patients with Acute Myeloid Leukemia.

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all- trans retinoic acid

New prognostic parameters for chronic myelomonocytic leukemia?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only